Atossa Genetics Stock Alpha and Beta Analysis
| ATOS Stock | USD 0.69 0.01 1.47% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Atossa Genetics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Atossa Genetics over a specified time horizon. Remember, high Atossa Genetics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Atossa Genetics' market risk premium analysis include:
Beta 2 | Alpha (0.32) | Risk 4.22 | Sharpe Ratio (0.07) | Expected Return (0.28) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Atossa Genetics Backtesting, Atossa Genetics Valuation, Atossa Genetics Correlation, Atossa Genetics Hype Analysis, Atossa Genetics Volatility, Atossa Genetics History and analyze Atossa Genetics Performance. Atossa Genetics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Atossa Genetics market risk premium is the additional return an investor will receive from holding Atossa Genetics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Atossa Genetics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Atossa Genetics' performance over market.| α | -0.32 | β | 2.00 |
Atossa Genetics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Atossa Genetics' Buy-and-hold return. Our buy-and-hold chart shows how Atossa Genetics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Atossa Genetics Market Price Analysis
Market price analysis indicators help investors to evaluate how Atossa Genetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Atossa Genetics shares will generate the highest return on investment. By understating and applying Atossa Genetics stock market price indicators, traders can identify Atossa Genetics position entry and exit signals to maximize returns.
Atossa Genetics Return and Market Media
The median price of Atossa Genetics for the period between Sat, Sep 27, 2025 and Fri, Dec 26, 2025 is 0.83 with a coefficient of variation of 13.34. The daily time series for the period is distributed with a sample standard deviation of 0.11, arithmetic mean of 0.86, and mean deviation of 0.09. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Guse Kyle of 5000 shares of Atossa Genetics at 1.48 subject to Rule 16b-3 | 10/09/2025 |
2 | Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference Laura Esserman, MD, MBA, to Discuss Active-Surveill... | 10/21/2025 |
3 | Atossa Highlights Emerging Opportunity for -Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication... | 11/17/2025 |
4 | Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying -Endoxifen as a Potential Therapeutic Candidate for G... | 12/02/2025 |
5 | Atossa Therapeutics Details Accelerated FDA Strategy to Advance -Endoxifen Across Breast Cancer Continuum | 12/04/2025 |
6 | Atossa Genetics Price Target Raised to 8.00 | 12/08/2025 |
7 | Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral -Endoxifen Formulations and Methods of Treating Patients Using -Endoxifen | 12/09/2025 |
8 | Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for -Endoxifen for Duchenne Muscular Dystrophy | 12/11/2025 |
9 | Has Atos Rebound and Turnaround Strategy in 2025 Created a Fresh Opportunity | 12/12/2025 |
10 | Atos Strengthens Leadership in Data AI in Spain as the Country Moves Towards AI at Scale | 12/17/2025 |
11 | Atos positionn comme un leader dans ltude NEAT 2025 de NelsonHall sur la transformation des oprations commerciales avec la GenAI | 12/19/2025 |
About Atossa Genetics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Atossa or other stocks. Alpha measures the amount that position in Atossa Genetics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Days Sales Outstanding | 237.79 | 190.34 | PTB Ratio | 1.66 | 1.58 |
Atossa Genetics Upcoming Company Events
As portrayed in its financial statements, the presentation of Atossa Genetics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atossa Genetics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Atossa Genetics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Atossa Genetics. Please utilize our Beneish M Score to check the likelihood of Atossa Genetics' management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Atossa Genetics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.